Inflammation Causes Exacerbation of COVID-19: How about Skin Inflammation?

Komine, Mayumi; Ansary, Tuba Mussarat; Hossain, Md Razib; Ohtsuki, Mamitaro

doi:10.3390/ijms232012260

Cited by 3 publications

(5 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…“Heat” represents an inflammatory response, 33 , 34 which is consistent with the fact that COVID-19 infection can cause an inflammatory response in the human body, 35–37 and the inflammatory state may worsen COVID-19 outcome, as reported in previous studies. 37 , 38 …”

Section: Discussionmentioning

confidence: 99%

“…"Heat" represents an inflammatory response, 33,34 which is consistent with the fact that COVID-19 infection can cause an inflammatory response in the human body, [35][36][37] and the inflammatory state may worsen COVID-19 outcome, as reported in previous studies. 37,38 The diagnosis of damp heat constitution is mainly based on several related issues concerning dampness and heat. People with a damp-heat constitution tend towards obesity, oily skin on the face or nose, a tendency to develop acne or boils, a frequent bitter taste or bad breath, loose or sticky stools, yellow urine, or a burning sensation in the urethra during urination, yellowish vaginal discharge in women, and dampness in the scrotal area in men.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Different Traditional Chinese Medicine Constitutions on the Clinical Outcomes of COVID-19 Patients Infected with SARS-CoV-2 Omicron Variant: A Retrospective Observational Study

Feng,

Qiu,

Hong

et al. 2023

IDR

View full text Add to dashboard Cite

Purpose Traditional Chinese Medicine (TCM) constitution and disease occurrence, development, and prognosis are interrelated. This study aimed to investigate the association between TCM constitution and the time to negative nucleic acid test results in patients with coronavirus disease 2019 (COVID-19) infected with the SARS-CoV-2 Omicron variant. Patients and Methods We identified COVID-19 patients (≥18 years) infected with the SARS-CoV-2 Omicron variant and collected clinical data, including clinical symptoms, time to negative nucleic acid test results, and TCM constitution. Linear and logistic regression analyses explored the relationship between TCM constitution and the time to negative nucleic acid test results in patients with the COVID-19 Omicron variant. Results We included 486 patients with COVID-19, with a mean age of 40.2 years; 321 (66.0%) men and 165 (34.0%) women. Balanced constitution accounted for 43.8%, and unbalanced constitution accounted for 56.2%. Chi-square test showed that different TCM constitutions had significant differences in the influence of clinical symptoms of COVID-19 patients (P < 0.01). After controlling for various factors, multiple linear regression analysis revealed that an unbalanced constitution was significantly positively correlated with time to negative nucleic acid test results (P < 0.05). After controlling for various factors, logistic regression analysis revealed that an unbalanced constitution was closely related to the 7-day nucleic acid test conversion rate (odds ratio (OR): 0.53, 95% confidence interval (CI): 0.36–0.80, P < 0.05). After dividing the unbalanced constitution into deficiency constitution and non-deficiency constitution, the non-deficiency constitution was closely associated with the 7-day nucleic acid test conversion rate (OR = 0.45, 95% CI: 0.28–0.74, P < 0.05). Further analysis revealed that damp-heat constitution in the non-deficiency constitution was associated with the 7-day nucleic acid test conversion rate (OR = 0.33, 95% CI: 0.18–0.60, P < 0.05). Conclusion In patients with COVID-19, an unbalanced constitution is associated with a longer time to negative nucleic acid test results and lower 7-day nucleic acid test conversion rates.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Impact of Different Traditional Chinese Medicine Constitutions on the Clinical Outcomes of COVID-19 Patients Infected with SARS-CoV-2 Omicron Variant: A Retrospective Observational Study

Feng,

Qiu,

Hong

et al. 2023

IDR

View full text Add to dashboard Cite

show abstract

“…Ряд данных могут косвенно подтвердить потенциальный терапевтический эффект циклоспорина А при SARS-CoV-2 инфекции. В неко торых исследованиях сообщается о низкой заболеваемости COVID-19 среди лиц, страдающих ревматическими заболеваниями [24,25], или о лучшем прогнозе у реципиентов трансплантата почки [26]. Иммуносупрессивное лечение на основе циклоспорина А может быть безопасным и эффективным для реципиентов трансплантата почки с диагнозом COVID-19 [26].…”

Section: Discussionunclassified

“…Факторы риска летального исхода: возраст старше 57,5 года, индекс массы тела более 30 кг/м 2 , сатурация ниже 85,5 % в день применения ИИЛ-6. Длительность госпитализации составила 18,5 (14-24) дня против 18 (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24) д ней, р = 0,778. ВЫВОДЫ: Циклоспорин А в дополнение к ГКС и ИИЛ-6 для терапии COVID-19 может способствовать снижению летальности, частоты поступления в ОРИТ и потребности в респираторной поддержке.…”

Section: ит при нки Covid-19unclassified

Cyclosporine A therapy in patients with COVID-19 and failure of immunosuppression therapy: a retrospective cohort propensity-score matched analysis

Merzhoeva,

Yaroshetskiy,

Savko

et al. 2023

Annals of Critical Care

View full text Add to dashboard Cite

INTRODUCTION: Therapy of COVID-19 patients with progressive lung damage after the use of glucocorticosteroids (GCS) and interleukin-6 inhibitors (IIL-6) has not yet been developed. OBJECTIVE: Assessment of the effectiveness of cyclosporine A in patients with COVID-19 with progression of lung damage and hypoxemic acute respiratory failure, who received therapy with GCS and IIL-6. MATERIALS AND METHODS: A retrospective cohort propensity-score matched analysis (n = 98). Cyclosporine A was prescribed in the first 72–96 hours after IIL-6 administration when the patient's condition worsened. The patients of comparison group corresponded to the study group, but did not receive cyclosporine A therapy. The primary end point was in-hospital mortality. Secondary endpoints — duration of hospitalization, number of patients admitted to the intensive care unit (ICU), need for respiratory support. RESULTS: Mortality was 12 (22) % in the cyclosporine group and 27 (61) % in the comparison group, р = 0.001 (hazard ratio [HR] 2.00 (1.12–3.48), р = 0.018), ICU admission rate 14 (26) % vs 29 (66) %, р = 0.001, respectively. In the cyclosporine group on day 7 CT-4, there were 26 % of patients vs 52 % in the control group, р = 0.014, the need for respiratory support (37 % vs 63.6 %, р = 0.011); saturation 88 % (82–93) vs 80 % (70–86), р = 0.001, respectively. The need for respiratory support at day 11 after IIL-6 increased the likelihood of death (HR 7.10 (2.5–20), р = 0.001). Risk factors for death: age over 57.5 years, body mass index over 30 kg/m2, hemoglobin oxygen saturation below 85.5 % on the day of IIL-6 application. Duration of hospitalization was 18.5 (14–24) days vs 18 (12–24) days, р = 0.778. CONCLUSIONS: Cyclosporine A in addition to GCS and IIL-6 for COVID-19 therapy may reduce mortality, ICU admissions, and respiratory support requirements.

show abstract

“…COVID-19 is a recently emerged viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Komine et al reviewed the basic nature of SARS-CoV-2, including the possible emergence pathways, mechanisms of infection, and exacerbation in patients with obesity, hypertension, diabetes mellitus, and pulmonary diseases [ 2 ]. The major inflammatory skin diseases, psoriasis and atopic dermatitis (AD), do not seem to cause poor prognosis for COVID-19 based on the epidemiological data so far.…”

mentioning

confidence: 99%